L-dopa improves colour vision in Parkinson's disease

  • Th. Büttner
  • W. Kuhn
  • T. Patzold
  • H. Przuntek
Full Papers

Summary

In recent studies disorders of colour vision in Parkinsonian patients have been demonstrated. Up to now, the influence of dopaminergic treatment on those phenomena remains unclear. We therefore performed a colour vision test (Farnsworth-Munsell 100 Hue Test) in 19 patients with Parkinson's disease before and aater the oral application of the morning dose of L-dopa. The colour discrimination was significantly improved after the ingestion of L-Dopa. There was no different effect of L-Dopa on the blue-yellow or red-green axis of colour vision. The morphological structures responsible for these colour vision disturbances are unknown, but it can be concluded that the dopamine deficiency in Parkinson's disease is not restricted to the basal ganglia but may involve the visual system as well.

Key words

Parkinson's disease colour vision colour discrimination Farnsworth Munsell 100 Hue Test L-Dopa 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders 3rd edn, revised. APA, Washington DC, USAGoogle Scholar
  2. Beck AT, Ward CJ, Mendelsohn M, Mock H, Erbaugh J (1961) An inventary for measuring depression. Arch Gen Psychiatry 4: 561–571Google Scholar
  3. Bodis-Wollner I, Yahr M (1978) Measurement of visual evoked potentials in Parkinson's disease. Brain 101: 661–671Google Scholar
  4. Bodis-Wollner I, Marx MC, Mitra S, Bobak P, Mylin L, Yahr M (1987) Visual dysfunction in parkinson's disease. Loss in spatiotemporal contrast sensitivity. Brain 110: 1675–1698Google Scholar
  5. Bodis-Wollner I, Tagliati M (1993) The visual system in Parkinson's disease. Adv Neurol 60: 390–394Google Scholar
  6. Büttner Th, Kuhn W, Klotz P, Steinberg R, Langkafel M, Przuntek H (1992) Disorders of color perception in Parkinson's disease. J Neurol 239 [Suppl 3]: S4Google Scholar
  7. Büttner Th, Kuhn W, Klotz P, Steinberg R, Voss L, Bulgaru D, Przuntek H (1993) Disturbance of colour perception in Parkinson's disease. J Neural Transm [PD-Sec] 6: 11–15Google Scholar
  8. Bulens C, Meerwaldt JD, van der Wildt GJ (1988) Effect of stimulus orientation on contrast sensitivity in Parkinson's disease. Neurology 38: 76–81Google Scholar
  9. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1993) Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 43: 367–373Google Scholar
  10. Farnsworth D (1943) The Farnsworth-Munsell 100-Hue and dichotomous test for color vision. J Opt Soc Am 33: 568–578Google Scholar
  11. Gawel MJ, Das P, Vincent S, Clifford Rose F (1981) Visual and auditory evoked responses in patients with parkinson's disease. J Neurol Neurosurg Psychiatry 44: 227–232Google Scholar
  12. Harnois C, Di Paolo T (1990) Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophtalmol Visual Sci 31: 2473–2475Google Scholar
  13. Hutton JT, Morris JL, Elias JW, Varma R, Poston JN (1991) Spatial contrast sensitivity ist reduced in bilateral Parkinson's disease. Neurology 41: 1200–1202Google Scholar
  14. Kinnear PR (1970) Proposals for scoring and assessing the 100-Hue-Test. Vision Res 10: 423–433Google Scholar
  15. Kramer SG (1971) Dopamine: a retinal neurotransmitter. I. Retinal uptake, storage, and light-stimulated release of H3-dopamine in vivo. Invest Ophtalmol Visual Sci 10: 438–452Google Scholar
  16. Kupersmith MJ, Shakin E, Siegel IM, Liebermann A (1982) Visual system abnormalities in patients with Parkinson's disease. Arch Neurol 39: 284–288Google Scholar
  17. Livingstone MS, Hubel DH (1984) Anatomy and physiology of a colour system in the primate visual cortex. J Neurosci 4: 309–356Google Scholar
  18. Mestre D, Blin O, Serratrice G, Pailhous J (1990) Spatiotemporal contrast sensitivity differs in normal aging and Parkinson's disease. Neurology 40: 1710–1714Google Scholar
  19. Montgomery Jr EB (1992) Pharmakokinetics and pharmakodynamics of levodopa. Neurology 42 [suppl 1]: 17–22Google Scholar
  20. Price MJ, Feldman RG, Adelberg D, Kayne H (1992) Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 42: 887–890Google Scholar
  21. Regan D, Maxner C (1987) Orientation-selective visual loss in patients with Parkinson's disease. Brain 110: 415–432Google Scholar
  22. Smith VC, Pokorny J, Pass AS (1985) Color-Axis determination on the Farnsworth-Munsell 100-Hue Test. Am J Ophtalmol 100: 176–182Google Scholar
  23. Sollazzo D (1985) Influence of L-Dopa/carbidopa on pattern reversal VEP: behavioural difference in primary and secondary parkinsonism. Electroencephalogr Clin Neurophysiol 61: 236–242Google Scholar
  24. Struck LK, Rodnitzki RL, Dobson JK (1990) Circadian fluctuations of contrast sensitivity. Neurology 40: 467–470Google Scholar
  25. Terziivanov D, Filipova M, Januk I, Balik J, Filip V, Stika L (1982) Changes in electroretinogram and serum potassium during L-Dopa treatment in parkinsonism. Arch Psychiatr Nervenkr 232: 507–513Google Scholar
  26. Verriest G, van Laethem J, Uvijls A (1982) A new assessment of the normal ranges of the Farnsworth-Munsell 100-Hue test scores. Am J Ophtamol 93: 635–642Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Th. Büttner
    • 1
  • W. Kuhn
    • 1
  • T. Patzold
    • 1
  • H. Przuntek
    • 1
  1. 1.Department of NeurologyRuhr-University Bochum, St. Josef-HospitalBochumFederal Republic of Germany

Personalised recommendations